Aclaris Therapeutics (ACRS) Accumulated Depreciation (2014 - 2025)

Aclaris Therapeutics' Accumulated Depreciation history runs 12 years deep, the most recent figure standing at $5.0 million for Q3 2025.

• In Q3 2025, Accumulated Depreciation rose 6.5% year-over-year to $5.0 million; the TTM figure through Sep 2025 stood at $5.0 million (up 6.5% YoY), while the FY2024 annual figure was $4.8 million, up 15.45% from the prior year.
• Accumulated Depreciation was $5.0 million for Q3 2025 at Aclaris Therapeutics, down from $5.0 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $5.0 million in Q2 2025 to a low of $2.9 million in Q1 2021.
• Historically, Accumulated Depreciation has averaged $4.1 million across 5 years, with a median of $4.2 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Accumulated Depreciation advanced 29.36% in 2021, then climbed 1.65% in 2024.
• A 5-year view of Accumulated Depreciation shows it stood at $3.4 million in 2021, then increased by 18.92% to $4.0 million in 2022, then increased by 3.15% to $4.2 million in 2023, then advanced by 15.45% to $4.8 million in 2024, then rose by 3.73% to $5.0 million in 2025.
• The last three Accumulated Depreciation figures came in at $5.0 million (Q3 2025), $5.0 million (Q2 2025), and $4.9 million (Q1 2025), per Business Quant data.